Emergex Vaccines Holding Limited, a biotechnology company developing population-based synthetic disease prophylaxis set-point vaccines in the field of infectious diseases, today announced it has successfully...
MRIGlobal yesterday announced that it has been awarded a $6.2 million, 5-year program from the Defense Threat Reduction Agency (DTRA) for the development of a vaccine for tularemia.
The award continues...
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
